RxDoctor Payments Data

Alexandre Demoraes, MD

Family Medicine · Napa, CANPI 1942284831

Payments from drug & device makers

$1,239in general payments, 2019–2025

Across 36 payments — averaging $34.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$225
  • Abbott$174
  • Novo Nordisk$143
  • AstraZeneca$125
  • Boehringer Ingelheim$95
  • Amgen$64
  • plus $414 from 14 others

What the payments were for

  • Food & beverage$1,239100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,239 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$239,041
Medicare patients
229
Services billed
10,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$98,517
XifaxanRifaximin17$27,367
OzempicSemaglutide25$26,725
GemtesaVibegron29$24,235
JardianceEmpagliflozin11$18,521
MyrbetriqMirabegron18$12,391
XareltoRivaroxaban21$11,510
JanuviaSitagliptin Phosphate11$8,600
EntrestoSacubitril/Valsartan11$8,359
TradjentaLinagliptin22$5,788
Atorvastatin Calcium290$4,091
Lubiprostone21$4,024
Levothyroxine Sodium259$3,677
Tamsulosin Hcl139$3,546
Desvenlafaxine Succinate ErDesvenlafaxine Succinate19$3,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$16$99,946194 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$39$27,36717 claims
Novo NordiskOzempic$143$26,72525 claims
Boehringer IngelheimJardiance, Tradjenta$95$24,30933 claims
Astellas Pharma US IncMyrbetriq$44$12,39118 claims
MerckJanuvia$14$8,60011 claims
NovartisEntresto$19$8,35911 claims
AbbVieSynthroid$42$1,90028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Napa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →